Sanofi announced that it has filed for premerger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) with the U.S. Department of Justice Antitrust Division and the Federal Trade Commission regarding its intention to acquire Medivation, Inc. (NASDAQ: MDVN). As announced on April 28, 2016, Sanofi proposed to acquire Medivation for $52.50 per share, representing an all-cash transaction valued at approximately $9.3 billion.
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. Sanofi is listed in Paris and in New York Media Relations
Jack Cox and Laurence Bollack
Tel. : +33 (0)1 53 77 46 46
Tel.: +33 (0)1 53 77 45 45
Tel.: + 1 908-981-5560